The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Sovaldi™ (sofosbuvir) and Hepatitis C

What is Sovaldi™ (sofosbuvir)?

On December 6, 2013, the U.S. Food and Drug Administration approved the prescription medication Sovaldi™ (sofosbuvir) as a component in a combination antiviral treatment regimen to treat chronic Hepatitis C infection, genotype 1, 2, 3, or 4, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplant) and those co-infected with Hepatitis C and HIV.

Sovaldi™ is a prescription once-daily oral nucleotide analog polymerase inhibitor to be used in combination with peginterferon alfa and ribavirin OR ribavirin. The active ingredient in this 400 mg tablet is sofosbuvir.